BRD2 and hepatocellular carcinoma: In this study, the proteomic data separated the HCC NAT samples into two subtypes by unsupervised clustering using the most variably expressed proteins, identifying two NAT subtypes associated with prognosis and recurrence, whereas no differences were found when using the transcriptomic data.